Day One Biopharmaceuticals
(NASDAQ) DAWN
Day One Biopharmaceuticals Financials at a Glance
Market Cap
$2.22B
Revenue (TTM)
$158.18M
Net Income (TTM)
$107.32M
EPS (TTM)
$-1.04
P/E Ratio
-20.58
Dividend
$0.00
Beta (Volatility)
0.00 (Low)
Dividend
$0.00
Beta (Volatility)
0.00 (Low)
Price
$21.46
Volume
109,330
Open
$21.44
Price
$21.46
Volume
109,330
Open
$21.44
Previous Close
$21.46
Daily Range
$21.42 - $21.47
52-Week Range
$5.63 - $21.47
Dividend
$0.00
Beta (Volatility)
0.00 (Low)
Price
$21.46
Volume
109,330
Open
$21.44
Previous Close
$21.46
Daily Range
$21.42 - $21.47
52-Week Range
$5.63 - $21.47
DAWN News
DAWN: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Day One Biopharmaceuticals
Industry
Biotechnology
Sector
Health CareEmployees
178
CEO
Jeremy Bender, PhD, MBA
Website
www.dayonebio.comHeadquarters
Brisbane, CA 94080, US
DAWN Financials
Key Financial Metrics (TTM)
Gross Margin
89%
Operating Margin
-81%
Net Income Margin
-68%
Return on Equity
-23%
Return on Capital
-29%
Return on Assets
-21%
Earnings Yield
-4.86%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$2.22B
Shares Outstanding
103.30M
Volume
109.33K
Short Interest
0.00%
Avg. Volume
4.38M
Financials (TTM)
Gross Profit
$140.97M
Operating Income
$127.75M
EBITDA
$105.82M
Operating Cash Flow
$103.76M
Capital Expenditure
$320.00K
Free Cash Flow
$104.08M
Cash & ST Invst.
$441.11M
Total Debt
$2.79M
Day One Biopharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$53.72M
+83.9%
Gross Profit
$47.64M
+81.6%
Gross Margin
88.68%
N/A
Market Cap
$2.22B
N/A
Market Cap/Employee
$12.24M
N/A
Employees
181
N/A
Net Income
$21.28M
+67.6%
EBITDA
$22.57M
+61.4%
Quarterly Fundamentals
Net Cash
$438.32M
-17.2%
Accounts Receivable
$26.73M
+92.7%
Inventory
$6.33M
+90.5%
Long Term Debt
$2.62M
+1.0%
Short Term Debt
$174.00K
+1640.0%
Return on Assets
-21.13%
N/A
Return on Invested Capital
-28.56%
N/A
Free Cash Flow
$17.65M
+43.8%
Operating Cash Flow
$14.15M
+52.8%